CI closed September's first trading day at $283.06, up 2.5% on the session and 1.3% on the week — a tidy recovery from July's post-earnings bruise, but one that hasn't shaken the short sellers who rebuilt positions through August.
The short rebuild flagged in the previous note has largely held. Short interest now runs at 2.14% of the free float — roughly 5.7 million shares — up 4.6% on the week and consistent with the directional drift that began in mid-August. The absolute level is still modest, but the persistence of that rebuild across four weeks is notable. What's changed since last week is borrow cost, which has dropped sharply: from around 0.45% a week ago to just 0.22% now, a 52% weekly decline and a multi-month low. That makes adding to a short position cheaper than at any point recently. Availability remains extraordinarily loose at 8,274% — for every share currently borrowed, there are roughly 83 more available in the lending pool — so there is no mechanical pressure on existing bears. Options tell a calmer story. The put/call ratio has dropped to 0.57, slightly below its 20-day average of 0.58 and well off the 0.65 spike recorded on August 31. The z-score of -0.40 places current options positioning just fractionally more bullish than normal — a mild contrast with the slow-burn short rebuild in the equity lending market.
The Street remains broadly constructive but with visible cracks forming around the edges. Thirteen analysts carry buy-equivalent ratings versus five holds, and the consensus mean target of $341 implies roughly 20% upside from current levels. That gap is doing a lot of work, however. The most recent analyst actions — both from early August — moved in the wrong direction: Jefferies downgraded to Hold with a $307 target, and Raymond James cut from Strong Buy to Outperform while trimming its target to $320. Both moves followed Q2 results that sent the stock down nearly 6% on the day and 7% over the subsequent week. Analysts who maintained positive ratings — Guggenheim to $361, Bernstein to $381, Morgan Stanley maintaining Overweight — largely did so by pointing to PBM growth, the Centene partnership, and the Signature rebate-free model buildout. The bear case centres on government-sector pricing pressure, political risk around pharmacy benefit management regulation, and what looks like sustained managed-care margin compression. The EV/EBITDA multiple has drifted down modestly over 30 days to 6.9x — not an alarming compression, but directionally consistent with the cautious analyst tone.
Institutional positioning offers a steadying counterpoint. BlackRock and Vanguard together hold more than 16% of shares outstanding, with both adding modestly in their most recent reported periods. Dodge & Cox, which added 618,000 shares as of June 30, is the most active builder among the top-ten holders. No activist has filed a Schedule 13D — all large-holder disclosures remain passive 13G filings. The one insider data point worth flagging is dated: CEO David Cordani bought just under $1 million in open-market shares in November 2025 at around $242. That's now sitting on a roughly 17% paper gain, but the trade is ten months old and the insider record has been quiet since.
The Q2 earnings reaction is worth keeping in mind as Q3 results approach. The last two prints produced first-day declines of 5.9% and 3.9%, with the five-day move after the most recent report extending to -7.2%. HUM and CVS both gained on the week — up 1.3% and 5.1% respectively — which suggests sector sentiment is not universally cautious; the pressure on CI appears more company-specific. The next earnings date is October 30. Between now and then, how borrow cost and short positioning evolve relative to the managed-care regulatory backdrop will be the positioning story worth tracking.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
